Vlad Dimoski Email

Associate Director, QA and Regulatory Compliance . Trillium Therapeutics

Current Roles

Employees:
17
Revenue:
$1.3M
About
Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective ᅢᄁ¬ツᆲᅤモdo not eatᅢᄁ¬ツᆲᅡン signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this ᅢᄁ¬ツᆲᅤモdo not eatᅢᄁ¬ツᆲᅡン signal with decoy receptors, we aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.
Trillium Therapeutics Address
Cambridge
Mississauga, null
Trillium Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.